GuiBin Wang

Dr. GuiBin Wang


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MFManru Fan
Manru Fan
QDQue Deng
Que Deng
ZLZhimin Li
Zhimin Li
GWGuiBin Wang
GuiBin Wang
MLMing Lu
Ming Lu
Post-stroke depression (PSD) is the most prevalent neuropsychological disorder among stroke survivors, affecting over 30% of patients. It significantly impairs patients’ quality of life and imposes a substantial burden on individuals, families, and society. Currently, the primary treatment for PSD focuses on conventional antidepressant therapies, with a lack of innovative approaches. Therefore, there is an urgent need to develop novel targeted therapies for PSD. This review synthesizes PSD pathogenesis as a multi-system network disorder involving monoamine deficits, neuroinflammation, HPA axis dysfunction, and neurotrophic imbalance. Within this framework, mesenchymal stem cells (MSCs) transplantation, as an emerging therapeutic strategy, may exert beneficial effects through anti-inflammatory, neuroprotective mechanisms, and the provision of neurotrophic factors. This review provides a preclinical framework that highlights the potential of MSC-based strategies, while emphasizing the need for further validation in PSD-specific models before clinical translation.

5 October 2026 in Nutrition Journal
Verified
Journal Article
Open access
PDF file
JLJinglin Lei
Jinglin Lei
LTLiu Tu
Liu Tu
HZHuiwen Zeng
Huiwen Zeng
HHHao Huang
Hao Huang
ZHZheng Hu
Zheng Hu
HLHaipeng Li
Haipeng Li
Background: The Composite Dietary Antioxidant Index (CDAI) is a novel and comprehensive metric for evaluating overall antioxidant capacity. However, the association of the CDAI with all-cause and cardiovascular disease (CVD) mortality among stroke survivors remains undefined. Methods: This study included 1,376 stroke survivors from the National Health and Nutrition Examination Survey (NHANES) spanning 1999 to 2018. Mortality outcomes were ascertained via the National Death Index. We utilized multivariate Cox regression models, incorporating restricted cubic spline plots, Kaplan-Meier survival analyses, and subgroup evaluations, to examine the link between CDAI and both all-cause and CVD mortality. Results: During the mean follow-up period of 86.4 months, a total of 587 participants died. The weighted Cox regression indicated that, a one-unit rise in CDAI corresponded to a 6% decline in all-cause mortality (HR = 0.94, 95% CI = 0.91–0.98, p = 0.001) and a 9% decline in CVD mortality (HR = 0.91, 95% CI = 0.86–0.97, p = 0.002). When comparing individuals in the quartile 1 with those in quartile 4, it was found that the latter exhibited a 44% reduced risk of all-cause mortality (HR = 0.56, 95% CI = 0.41–0.76, p < 0.001) and a 62% decreased risk of mortality due to CVD (HR = 0.38, 95% CI = 0.21–0.70, p = 0.002). Conclusion: The CDAI is inversely associated with all-cause and CVD mortality among stroke survivors. Specifically, higher CDAI levels are significantly linked to reduced risks of both all-cause and CVD mortality. Clinical trial number: Not application.